Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Osteoporosis Reports
Erschienen in: Current Osteoporosis Reports 3/2014

01.09.2014 | Bone Quality in Osteoporosis (MD Grynpas and JS Nyman, Section Editors)

Collagen Modifications in Postmenopausal Osteoporosis: Advanced Glycation Endproducts May Affect Bone Volume, Structure and Quality

verfasst von: Thomas L. Willett, Julia Pasquale, Marc D. Grynpas

Erschienen in: Current Osteoporosis Reports | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The classic model of postmenopausal osteoporosis (PM-OP) starts with the depletion of estrogen, which in turn stimulates imbalanced bone remodeling, resulting in loss of bone mass/volume. Clinically, this leads to fractures because of structural weakness. Recent work has begun to provide a more complete picture of the mechanisms of PM-OP involving oxidative stress and collagen modifications known as advanced glycation endproducts (AGEs). On one hand, AGEs may drive imbalanced bone remodeling through signaling mediated by the receptor for AGEs (RAGE), stimulating resorption and inhibiting formation. On the other hand, AGEs are associated with degraded bone material quality. Oxidative stress promotes the formation of AGEs, inhibits normal enzymatically derived crosslinking and can degrade collagen structure, thereby reducing fracture resistance. Notably, there are multiple positive feedback loops that can exacerbate the mechanisms of PM-OP associated with oxidative stress and AGEs. Anti-oxidant therapies may have the potential to inhibit the oxidative stress based mechanisms of this disease.
Literatur
1.•
Cervellati C, Bonaccorsi G, Cremonini E, Bergamini CM, Patella A, Castaldini C, et al. Bone mass density selectively correlates with serum markers of oxidative damage in postmenopausal women. Clin Chem Lab Med. 2013;51:333–8. Recent clinical evidence that oxidative stress and bone mass/volume loss are associated in PM-OP.PubMed
2.
Sendur OF, Turan Y, Tastaban E, Serter M. Antioxidant status in patients with osteoporosis: a controlled study. Joint Bone Spine. 2009;76:514–8.PubMedCrossRef
3.
Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, et al. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab. 2003;88:1523–7.PubMedCrossRef
4.
Muthusami S, Ramachandran I, Muthusamy B, Vasudevan G, Prabhu V, Subramaniam V, et al. Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin Chim Acta. 2005;360:81–6.PubMedCrossRef
5.
Hamada Y, Fujii H, Fukagawa M. Role of oxidative stress in diabetic bone disorder. Bone. 2009;45 Suppl 1:S35–8.PubMedCrossRef
6.•
Grune T, Catalgol B, Jung T. Oxidative stress and protein oxidation. In: Protein Oxidation and Aging: John Wiley and Sons; 2013, p. 1–214. A good review of oxidative stress and protein oxidation with sections on various diseases including osteoporosis.
7.
Avery NC, Bailey AJ. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol. 2006;54:387–95.PubMedCrossRef
8.
Biemel KM, Reihl O, Conrad J, Lederer MO. Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor. J Biol Chem. 2001;276:23405–12.PubMedCrossRef
9.
Sell DR, Nagaraj RH, Grandhee SK, Odetti P, Lapolla A, Fogarty J, et al. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Rev. 1991;7:239–51.PubMedCrossRef
10.
Hein G, Weiss C, Lehmann G, Niwa T, Stein G, Franke S. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis. 2006;65:101–4.PubMedCentralPubMedCrossRef
11.
Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, et al. RAGE is a multi-ligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci. 2002;59:1117–28.PubMedCrossRef
12.
Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008;19:329–37.PubMedCrossRef
13.
Verzijl N, Degroot J, Oldehinkel E, Bank RA, Thorpe SR, Baynes JW, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J. 2000;350(Pt 2):381–7.PubMedCentralPubMedCrossRef
14.
Verzijl N, Degroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem. 2000;275:39027–31.PubMedCrossRef
15.••
Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21:195–214. An excellent and comprehensive review of bone collagen crosslinking and the changes associated with loss of bone quality in various diseases including osteoporosis and diabetes mellitus.PubMedCrossRef
16.
Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci. 2005;1043:710–7.PubMedCrossRef
17.
Hein GE. Glycation endproducts in osteoporosis—is there a pathophysiologic importance? Clin Chim Acta. 2006;371:32–6.PubMedCrossRef
18.••
Saito M, Marumo K, Kida Y, Ushiku C, Kato S, Takao-Kawabata R, et al. Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1–34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos Int. 2011;22:2373–83. An important study of bone collagen crosslinking changes in a primate OVX model of PM-OP.PubMedCrossRef
19.••
Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int. 2010;21:655–66. This important study gives evidence for the important role of oxidative stress in altering bone collagen crosslinking (decreased enzymatic and increased pentosidine crosslinking). Furthermore, it demonstrates one of the ways raloxifene may imparts its beneficial effects and the role of hyperhomocysteinemia in increasing oxidative stress and increasing pentosidine content.PubMedCrossRef
20.
Saito M, Fujii K, Soshi S, Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int. 2006;17:986–95.PubMedCrossRef
21.
McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2001;2:16.PubMedCentralPubMed
22.
Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282:27285–97.PubMedCentralPubMedCrossRef
23.•
Goettsch C, Babelova A, Trummer O, Erben RG, Rauner M, Rammelt S, et al. NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Invest. 2013;123:4731–8. This study highlights the role of NOX4 in osteoclastogenesis. This may link increased oxidative stress and increase bone resorption in PM-OP.PubMedCentralPubMedCrossRef
24.
Almeida M, Han L, Ambrogini E, Bartell SM, Manolagas SC. Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens. Mol Endocrinol. 2010;24:2030–7.PubMedCentralPubMedCrossRef
25.
Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9.PubMedCrossRef
26.
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–12.PubMedCrossRef
27.•
Fleming TH, Humpert PM, Nawroth PP, Bierhaus A. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process – a mini-review. Gerontology. 2010;57(5):435–43. The paper presents a model of the negative effects of AGE/RAGE mediated cellular dysfunction that can be applied to better understand PM-OP.
28.
Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med. 2006;203:1067–80.PubMedCentralPubMedCrossRef
29.
McCarthy AD, Etcheverry SB, Cortizo AM. Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol. 1999;36:45–52.PubMedCrossRef
30.
Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun. 2006;340:1091–7.PubMedCrossRef
31.
Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, et al. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res. 1997;12:439–46.PubMedCrossRef
32.
Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol. 1997;8:260–70.PubMed
33.
Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17:1514–23.PubMedCrossRef
34.
Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation end products influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem. 2007;113:154–61.PubMedCrossRef
35.
McCarthy AD, Etcheverry SB, Bruzzone L, Cortizo AM. Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol Cell Biochem. 1997;170:43–51.PubMedCrossRef
36.
Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40:345–53.PubMedCentralPubMedCrossRef
37.
Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269:9889–97.PubMed
38.
Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–9.PubMedCrossRef
39.
Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280:E685–94.PubMed
40.
Oxlund H, Mosekilde L, Ortoft G. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone. 1996;19:479–84.PubMedCrossRef
41.
Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int. 2006;79:160–8.PubMedCrossRef
42.
Opsahl W, Zeronian H, Ellison M, Lewis D, Rucker RB, Riggins RS. Role of copper in collagen cross-linking and its influence on selected mechanical properties of chick bone and tendon. J Nutr. 1982;112:708–16.PubMed
43.
Masse PG, Rimnac CM, Yamauchi M, Coburn SP, Rucker RB, Howell DS, et al. Pyridoxine deficiency affects biomechanical properties of chick tibial bone. Bone. 1996;18:567–74.PubMedCrossRef
44.
Oxlund H, Barckman M, Ortoft G, Andreassen TT. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone. 1995;17:365S–71.PubMed
45.
Kafantari H, Kounadi E, Fatouros M, Milonakis M, Tzaphlidou M. Structural alterations in rat skin and bone collagen fibrils induced by ovariectomy. Bone. 2000;26:349–53.PubMedCrossRef
46.
Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. 2008;42:456–66.PubMedCrossRef
47.
Landis WJ, Jacquet R. Association of calcium and phosphate ions with collagen in the mineralization of vertebrate tissues. Calcif Tissue Int. 2013;93:329–37.PubMedCrossRef
48.
Eyre DR, Weis MA. Bone collagen: new clues to its mineralization mechanism from recessive osteogenesis imperfecta. Calcif Tissue Int. 2013;93:338–47.PubMedCrossRef
49.
Gupta HS, Zioupos P. Fracture of bone tissue: the 'hows' and the 'whys'. Med Eng Phys. 2008;30:1209–26.PubMedCrossRef
50.
Nyman JS, Roy A, Tyler JH, Acuna RL, Gayle HJ, Wang X. Age-related factors affecting the postyield energy dissipation of human cortical bone. J Orthop Res. 2007;25:646–55.PubMedCentralPubMedCrossRef
51.
Nyman JS, Roy A, Acuna RL, Gayle HJ, Reyes MJ, Tyler JH, et al. Age-related effect on the concentration of collagen crosslinks in human osteonal and interstitial bone tissue. Bone. 2006;39:1210–7.PubMedCentralPubMedCrossRef
52.
Wang X, Li X, Shen X, Agrawal CM. Age-related changes of noncalcified collagen in human cortical bone. Ann Biomed Eng. 2003;31:1365–71.PubMedCrossRef
53.
Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone. 2002;31:1–7.PubMedCrossRef
54.
Wang X, Bank RA, Tekoppele JM, Hubbard GB, Athanasiou KA, Agrawal CM. Effect of collagen denaturation on the toughness of bone. Clin Orthop Relat Res. 2000;371:228–39.
55.
Zioupos P, Currey JD, Hamer AJ. The role of collagen in the declining mechanical properties of aging human cortical bone. J Biomed Mater Res. 1999;45:108–16.PubMedCrossRef
56.
Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28:195–201.PubMedCrossRef
57.
Tang SY, Vashishth D. The relative contributions of non-enzymatic glycation and cortical porosity on the fracture toughness of aging bone. J Biomech. 2011;44:330–6.PubMedCentralCrossRef
58.
Tang SY, Vashishth D. Non-enzymatic glycation alters microdamage formation in human cancellous bone. Bone. 2010;46:148–54.PubMedCrossRef
59.•
Willett TL, Sutty S, Gaspar A, Avery N, Grynpas M. In vitro non-enzymatic ribation reduces postyield strain accommodation in cortical bone. Bone. 2013;52:611–22. This paper draws attention to the short comings of the ribation model.PubMedCrossRef
60.
Biemel KM, Friedl DA, Lederer MO. Identification and quantification of major Maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J Biol Chem. 2002;277:24907–15.PubMedCrossRef
61.
Sell DR, Biemel KM, Reihl O, Lederer MO, Strauch CM, Monnier VM. Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. J Biol Chem. 2005;280:12310–5.PubMedCrossRef
62.••
Gallant MA, Brown DM, Hammond M, Wallace JM, Du J, Deymier-Black AC, et al. Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. Bone. 2014;61:191–200. A very interesting study suggesting that the positive effects of raloxifene on bone quality and in treating osteoporosis may be partly cell-independent. In vitro soaking of bone specimens in a raloxifene solution improved ductility.PubMedCrossRef
63.
Allen MR, Hogan HA, Hobbs WA, Koivuniemi AS, Koivuniemi MC, Burr DB. Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology. 2007;148:3908–13.PubMedCrossRef
64.
Allen MR, Iwata K, Sato M, Burr DB. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone. 2006;39:1130–5.PubMedCrossRef
65.
Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci. 2005;1043:807–16.PubMedCrossRef
66.
Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci. 2005;62:1671–81.PubMedCrossRef
Metadaten
Titel
Collagen Modifications in Postmenopausal Osteoporosis: Advanced Glycation Endproducts May Affect Bone Volume, Structure and Quality
verfasst von
Thomas L. Willett
Julia Pasquale
Marc D. Grynpas
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Current Osteoporosis Reports / Ausgabe 3/2014
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0214-3

Weitere Artikel der Ausgabe 3/2014

Current Osteoporosis Reports 3/2014 Zur Ausgabe

Skeletal Genetics (ML Johnson and S Ralston, Section Editors)

Sclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments

Skeletal Genetics (ML Johnson and S Ralston, Section Editors)

Hypophosphatemic Rickets: Revealing Novel Control Points for Phosphate Homeostasis

Pediatrics (M Leonard and L Ward, Section Editors)

Glucocorticoid-Associated Osteoporosis in Chronic Inflammatory Diseases: Epidemiology, Mechanisms, Diagnosis, and Treatment

Pediatrics (M Leonard and L Ward, Section Editors)

Underweight, Overweight, and Pediatric Bone Fragility: Impact and Management

Pediatrics (M Leonard and L Ward, Section Editors)

Osteogenesis Imperfecta: Diagnosis and Treatment

Hot Topic

Aneuploidy and Skeletal Health

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Traumatologische Notfälle Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise